2 ml tirzepatide vial Injectable – 25 mg/mL Tirzepatide Instructions | Allure Medical

The FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD).The approval is based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy statistically significantly r

GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc

The worldwide prevalence is projected to soar to []

PlexusDx explains what causes these symptoms and practical steps to minimize discomfort while losing weight

Understanding your coverage requires knowing the difference between branded and compounded medications, how prior authorization works, and what out-of-pocket alternatives exist when coverage is

Obesity is a chronic, relapsing disease associated with multiple complications and a substantial morbidity, mortality and health care burden